• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发一种计算器,用于确定急诊科治疗镰状细胞病血管闭塞性发作的个体化阿片类药物剂量。

Development of a Calculator to Determine Individualized Opioid Doses for Treatment of Vaso-Occlusive Episodes for Sickle Cell Disease in the Emergency Department.

作者信息

Kavanagh Patricia L, Strouse John J, Paice Judith A, Ibemere Stephanie O, Tanabe Paula

出版信息

Jt Comm J Qual Patient Saf. 2025 Jan;51(1):74-79. doi: 10.1016/j.jcjq.2024.10.002. Epub 2024 Oct 17.

DOI:10.1016/j.jcjq.2024.10.002
PMID:39581832
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11700749/
Abstract

Sickle cell disease (SCD) is a life-limiting multisystem disease primarily affecting individuals of African and Latinx descent. Its most common complication is painful vaso-occlusive episodes (VOEs), which is also the most common reason individuals with SCD seek care in the emergency department (ED). National guidelines recommend the use of standardized approaches to pain management in the ED, preferably using pain management plans tailored to each patient. However, no standard approach to developing these plans exists. This article describes the development of an opioid calculator to help SCD clinicians create individualized plans to better manage acute painful VOE in the ED setting.

摘要

镰状细胞病(SCD)是一种危及生命的多系统疾病,主要影响非洲裔和拉丁裔个体。其最常见的并发症是疼痛性血管闭塞发作(VOE),这也是SCD患者到急诊科(ED)就诊的最常见原因。国家指南建议在急诊科采用标准化的疼痛管理方法,最好使用针对每个患者量身定制的疼痛管理计划。然而,目前尚不存在制定这些计划的标准方法。本文描述了一种阿片类药物计算器的开发,以帮助SCD临床医生制定个性化计划,以便在急诊科环境中更好地管理急性疼痛性VOE。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/5479672d13e1/nihms-2038122-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/11ff0807846d/nihms-2038122-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/bda3a41875ef/nihms-2038122-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/804ae6756fb7/nihms-2038122-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/5479672d13e1/nihms-2038122-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/11ff0807846d/nihms-2038122-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/bda3a41875ef/nihms-2038122-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/804ae6756fb7/nihms-2038122-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/454c/11700749/5479672d13e1/nihms-2038122-f0004.jpg

相似文献

1
Development of a Calculator to Determine Individualized Opioid Doses for Treatment of Vaso-Occlusive Episodes for Sickle Cell Disease in the Emergency Department.开发一种计算器,用于确定急诊科治疗镰状细胞病血管闭塞性发作的个体化阿片类药物剂量。
Jt Comm J Qual Patient Saf. 2025 Jan;51(1):74-79. doi: 10.1016/j.jcjq.2024.10.002. Epub 2024 Oct 17.
2
Exploring Emergency Department Provider Experiences With and Perceptions of Weight-Based Versus Individualized Vaso-Occlusive Treatment Protocols in Sickle Cell Disease.探索急诊科医护人员对镰状细胞病基于体重与个体化血管闭塞性治疗方案的体验及看法。
Adv Emerg Nurs J. 2019 Jan-Mar;41(1):86-97. doi: 10.1097/TME.0000000000000232.
3
Trends and hospital practice variation for analgesia for children with sickle cell disease with vaso-occlusive pain episodes: An 11-year analysis.镰状细胞病血管阻塞性疼痛发作患儿镇痛的趋势和医院实践变化:11 年分析。
Am J Emerg Med. 2024 Dec;86:129-134. doi: 10.1016/j.ajem.2024.10.028. Epub 2024 Oct 13.
4
Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department.改善儿科急诊部血管阻塞性发作的管理。
Pediatrics. 2015 Oct;136(4):e1016-25. doi: 10.1542/peds.2014-3470. Epub 2015 Sep 21.
5
Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department.个体化疼痛方案对急诊科治疗镰状细胞病血管阻塞性发作的影响。
Blood Adv. 2024 Oct 22;8(20):5330-5338. doi: 10.1182/bloodadvances.2023012439.
6
An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization.一种创新的短期住院医疗模式,用于治疗加拿大成人镰状细胞病患者的单纯血管阻塞性危象,以减少急诊科的使用。
CJEM. 2019 Jan;21(1):55-62. doi: 10.1017/cem.2017.413. Epub 2017 Oct 17.
7
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.成人疼痛性镰状细胞血管闭塞性危象的药物干预措施。
Cochrane Database Syst Rev. 2019 Nov 14;2019(11):CD012187. doi: 10.1002/14651858.CD012187.pub2.
8
Do children with sickle cell disease receive disparate care for pain in the emergency department?患有镰状细胞病的儿童在急诊科接受的疼痛治疗是否存在差异?
J Emerg Med. 2010 Nov;39(5):691-5. doi: 10.1016/j.jemermed.2009.06.003. Epub 2009 Aug 22.
9
A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD).一项比较两种镰状细胞病(SCD)血管阻塞性发作(VOE)方案的随机对照试验。
Am J Hematol. 2018 Feb;93(2):159-168. doi: 10.1002/ajh.24948. Epub 2017 Nov 10.
10
An Interrupted Time Series Analysis of the Dissemination of a Sickle Cell Vaso-Occlusive Episode Treatment Algorithm and a Case Management Referral Form for Individuals With Sickle Cell Disease in the Emergency Department.一项镰状细胞血管阻塞性发作治疗算法和镰状细胞病患者病例管理转诊表在急诊科传播的中断时间序列分析。
J Emerg Nurs. 2021 Jan;47(1):40-49.e1. doi: 10.1016/j.jen.2020.06.001. Epub 2020 Aug 18.

本文引用的文献

1
A comparison of the effect of patient-specific versus weight-based protocols to treat vaso-occlusive episodes in the emergency department.比较患者特异性与基于体重的方案在急诊科治疗血管阻塞性发作的效果。
Acad Emerg Med. 2023 Dec;30(12):1210-1222. doi: 10.1111/acem.14805. Epub 2023 Nov 12.
2
Sickle Cell Disease: A Review.镰状细胞病:综述。
JAMA. 2022 Jul 5;328(1):57-68. doi: 10.1001/jama.2022.10233.
3
A Comparison of Institutional Opioid Equianalgesia Tools: A National Study.机构阿片类药物等效工具比较:一项全国性研究。
J Palliat Med. 2022 Nov;25(11):1686-1691. doi: 10.1089/jpm.2021.0678. Epub 2022 May 13.
4
Alternatives to opioid protocols in Colorado emergency departments reduce opioid use without changing reported pain.科罗拉多州急诊科采用的非阿片类药物方案替代措施在不改变报告疼痛程度的情况下减少了阿片类药物的使用。
J Am Coll Emerg Physicians Open. 2020 Oct 12;1(6):1493-1499. doi: 10.1002/emp2.12263. eCollection 2020 Dec.
5
Trial design of comparing patient-specific versus weight-based protocols to treat vaso-occlusive episodes in sickle cell disease (COMPARE-VOE).比较特定患者与基于体重的方案治疗镰状细胞病血管阻塞性发作的临床试验设计(COMPARE-VOE)。
Contemp Clin Trials. 2021 Feb;101:106252. doi: 10.1016/j.cct.2020.106252. Epub 2020 Dec 28.
6
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.美国血液学会2020年镰状细胞病指南:急性和慢性疼痛的管理
Blood Adv. 2020 Jun 23;4(12):2656-2701. doi: 10.1182/bloodadvances.2020001851.
7
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.成人癌症疼痛,第 3.2019 版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Aug 1;17(8):977-1007. doi: 10.6004/jnccn.2019.0038.
8
Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: The emergency department providers' perspective.北卡罗来纳州中部照顾镰状细胞病患者的障碍和促进因素:急诊提供者的观点。
PLoS One. 2019 May 7;14(5):e0216414. doi: 10.1371/journal.pone.0216414. eCollection 2019.
9
Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit.镰状细胞病成人患者的阿片类药物剂量与急性护理利用结果:急诊科与急性护理病房对比
Am J Emerg Med. 2018 Jan;36(1):88-92. doi: 10.1016/j.ajem.2017.07.037. Epub 2017 Jul 13.
10
Patterns of opioid use in sickle cell disease.镰状细胞病中阿片类药物的使用模式。
Am J Hematol. 2016 Nov;91(11):1102-1106. doi: 10.1002/ajh.24498. Epub 2016 Aug 8.